ADAP
Price:
$0.6229
Market Cap:
$159.39M
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sar...[Read more]
Industry
Biotechnology
IPO Date
2015-05-06
Stock Exchange
NASDAQ
Ticker
ADAP
According to Adaptimmune Therapeutics plc’s latest financial reports and current stock price. The company's current Current Ratio is 3.85. This represents a change of 22.11% compared to the average of 3.15 of the last 4 quarters.
The mean historical Current Ratio of Adaptimmune Therapeutics plc over the last ten years is 5.67. The current 3.85 Current Ratio has changed 6.69% with respect to the historical average. Over the past ten years (40 quarters), ADAP's Current Ratio was at its highest in in the September 2020 quarter at 12.23. The Current Ratio was at its lowest in in the March 2015 quarter at 0.
Average
5.67
Median
4.45
Minimum
1.02
Maximum
11.03
Discovering the peaks and valleys of Adaptimmune Therapeutics plc Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 982.86%
Maximum Annual Current Ratio = 11.03
Minimum Annual Increase = -62.90%
Minimum Annual Current Ratio = 1.02
Year | Current Ratio | Change |
---|---|---|
2023 | 2.85 | -27.98% |
2022 | 3.96 | -40.40% |
2021 | 6.64 | -34.81% |
2020 | 10.19 | 190.43% |
2019 | 3.51 | -62.90% |
2018 | 9.46 | 205.31% |
2017 | 3.10 | -37.24% |
2016 | 4.94 | -55.25% |
2015 | 11.03 | 982.86% |
2014 | 1.02 | 152.10% |
The current Current Ratio of Adaptimmune Therapeutics plc (ADAP) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
4.48
5-year avg
5.43
10-year avg
5.67
Adaptimmune Therapeutics plc’s Current Ratio is less than Stoke Therapeutics, Inc. (5.09), less than Homology Medicines, Inc. (4.19), less than Black Diamond Therapeutics, Inc. (5.55), greater than Harpoon Therapeutics, Inc. (1.89), less than Mereo BioPharma Group plc (6.10), less than Pieris Pharmaceuticals, Inc. (4.82), greater than PDS Biotechnology Corporation (2.84), less than Leap Therapeutics, Inc. (3.97), greater than Affimed N.V. (1.93), greater than Corvus Pharmaceuticals, Inc. (0.92), greater than Aptose Biosciences Inc. (1.05), less than Nkarta, Inc. (12.91), less than Agios Pharmaceuticals, Inc. (8.99), less than Pliant Therapeutics, Inc. (10.26), less than Adicet Bio, Inc. (10.64), less than MiNK Therapeutics, Inc. (888.66), less than ImmunoGen, Inc. (5.47), greater than Sangamo Therapeutics, Inc. (1.35),
Company | Current Ratio | Market cap |
---|---|---|
5.09 | $702.34M | |
4.19 | $3.02M | |
5.55 | $138.07M | |
1.89 | $865.08M | |
6.10 | $597.28M | |
4.82 | $22.44M | |
2.84 | $80.06M | |
3.97 | $121.08M | |
1.93 | $35.33M | |
0.92 | $515.34M | |
1.05 | $11.27M | |
12.91 | $175.72M | |
8.99 | $2.62B | |
10.26 | $883.59M | |
10.64 | $87.35M | |
888.66 | $26.19M | |
5.47 | $8.73B | |
1.35 | $406.86M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Adaptimmune Therapeutics plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Adaptimmune Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Adaptimmune Therapeutics plc's Current Ratio?
How is the Current Ratio calculated for Adaptimmune Therapeutics plc (ADAP)?
What is the highest Current Ratio for Adaptimmune Therapeutics plc (ADAP)?
What is the 3-year average Current Ratio for Adaptimmune Therapeutics plc (ADAP)?
What is the 5-year average Current Ratio for Adaptimmune Therapeutics plc (ADAP)?
How does the current Current Ratio for Adaptimmune Therapeutics plc (ADAP) compare to its historical average?